Patrick Zenner, Roche Labs senior VP-pharmaceuticals, is moving to corporate headquarters in Basel on two-year assignment as director of project management and drug regulatory affairs. Zenner, who was also a member of the Roche executive committee and board, will assume his new position Jan. 1, 1989. He will remain at the parent company for two years, to "facilitate and enhance cooperation and collaboration between Basel and Nutley (N.J.) in the critical areas related to international development and registration of pharmaceutical products," according to a Roche announcement of the move.
You may also be interested in...
The firm’s acute migraine treatment Nurtec ODT generated $65m in 2020 after launching a year ago. Biohaven aims for Nurtec to become the leader in what could be a $4bn-$5bn category in the US.
The Q-Collar is meant to work by improving blood flow to the brain, and has been shown to reduce signs of trauma from head impacts when playing sports.
The device can conduct laparoscopic hysterectomies, giving surgeons more mobility while leaving less scarring.